HER2 signaling pathway and trastuzumab cardiotoxicity

By Criscitiello Carmen   Curigliano Giuseppe  

Future Oncology, Vol. 9, Iss. 2, 2013-02 ,pp. : 179-181

Future Medicine

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

Dietary Flaxseed-Trastuzumab Interactive Effects on the Growth of HER2-Overexpressing Human Breast Tumors (BT-474)

By Mason Julie K.   Fu Ming-Hua   Chen Jianmin   Yu Zhe   Thompson Lilian U.  

Nutrition and Cancer, Vol. 65, Iss. 3, 2013-04 ,pp. : 451-459

Routledge Ltd

Access to resources Recommend Favorite

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

By Zagouri Flora  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 13-22

Springer Publishing Company

Access to resources Recommend Favorite

Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment

By                      

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 1887-1892

Spandidos Publications

Access to resources Recommend Favorite